Drug intelligence / Profile preview

INS-R2T

Development stage: Preclinical
Lead developer: Lamark
Modality: Peptides
Administration: Oral

Overview

INS-R2T is an investigational oral insulin formulation being developed by Lamark Biotech for the treatment of diabetes. The drug utilizes Lamark's proprietary InStrong™ technology, which acts as a "molecular shield" to protect peptide therapeutics from enzymatic degradation and acidic conditions within the gastrointestinal tract. By facilitating the transport of insulin across the intestinal epithelium into the systemic circulation, INS-R2T aims to provide a non-invasive alternative to traditional subcutaneous insulin injections. This oral delivery approach is intended to improve patient adherence and provide a more physiological portal delivery of insulin. The program is currently in the IND-enabling stage of development.

Other names: InStrong oral insulin

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on INS-R2T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INS-R2T.

Explore the full profile